Dental Product Shopper met with PeriRx on the show floor and learned about the impending launch of its newest product—the SaliMark OSCC: Oral Cancer Salivary Diagnostic Test—by the end of the first quarter 2015.
PeriRx expects this to break through current trends in detecting oral cancer says MIchael Ventriello, Public Relations and Marketing Advisor (left). SaliMark OSCC allows dentists to perform a saliva test if they notice something suspicious in a patient’s mouth. A patient gives a sample of their saliva in a bottle, which preserves the molecular DNA, which is then sent to a lab for risk assessment. Within a few days, results show either a low, moderate, or high risk of oral cancer. If the risk is moderate to high, a second opinion is obtained from a specialist regarding the decision to perform a biopsy.
According to Chief Medical Officer Jack Martin (right), this expedited process is accurate in determining whether or not a patient should be referred for a biopsy. It also has the potential to eliminate the invasive treatment that a biopsy entails, especially since more than 90% are reported as negative.
SaliMark OSCC is designed to get patients tested for oral cancer early, preventing further damage and enhancing patient quality of life.